Webinars

Better diagnosis of childhood eye cancers

Retinoblastoma is a childhood eye cancer, which usually occurs before the age of three. The cause is almost always genetic - and results from defects in a gene called RB1. 

These defects can be identified through genetic sequencing of DNA taken from retinoblastoma patients' blood and/or tumours. Currently, the only way to analyse tumour DNA is by removing the eye, so affected children have to go under general anaesthetic. 

Dr Amy Gerrish at Birmingham Children's Hospital is working on a test that will allow researchers to identify Rb in patients who have not had their eye removed.

In this webinar, she will spotlight her research, leading to better childhood cancer diagnosis. Dr Gerrish will be joined by Fight for Sight's Ambassador, Katie Elliott, who aged four was diagnosed with retinoblastoma.  

Save the date: Thursday 6 March 2025 at 12:00-13:00.

Sign up for this free webinar now

 

A young Katie Elliot in riding gear standing next to a horse.

“I began riding in shows at six. Other people didn’t think I’d be able to compete, but I proved them wrong.”

Katie Elliott Model Katie Elliott, has adapted after losing her eye to Retinoblastoma
Read Katie's story

About the speakers

Dr Amy Gerrish is a Research Scientist at the West Midlands Regional Genetics Laboratory, which is part of the Birmingham Women's and Children's NHS Foundation Trust, UK.

She is interested in the application of cell-free DNA analysis in clinical diagnostics.

Her current research areas include noninvasive prenatal diagnosis of single-gene disorders and liquid biopsy diagnosis of retinoblastoma

Read more about how we funded her research

Katie Elliott, following the diagnosis of retinoblastoma, endured year-long chemotherapy and the removal of one of her eyes. She had a prosthetic eye fitted and is now a model and advocate, using TikTok as a platform to spread positive messaging around confidence and disability. 

  • 1 in 20,000
    children in the UK are affected by retinoblastoma

Who will benefit from this webinar?

The webinar is a unique opportunity to hear from a leading researcher in the field of genetics and eye disease. 

The session will interest